Brief: Beam Therapeutics Says All 7 Patients Treated With Beam-101 Achieved Durable Increases In Fetal Hemoglobin, Reductions In Sickle Hemoglobin
07/12/2024 16:30
Dec 7 (Reuters) - Beam Therapeutics Inc BEAM.O :
* BEAM THERAPEUTICS ANNOUNCES NEW DATA FROM BEACON PHASE 1/2
CLINICAL TRIAL OF BEAM-101 IN SICKLE CELL DISEASE AT ASH ANNUAL
MEETING
* BEAM THERAPEUTICS: INITIAL SAFETY PROFILE CONSISTENT WITH
BUSULFAN CONDITIONING AND AUTOLOGOUS HEMATOPOIETIC STEM CELL
TRANSPLANTATION
* BEAM THERAPEUTICS: ALL 7 PATIENTS TREATED WITH BEAM-101
ACHIEVED
DURABLE INCREASES IN FETAL HEMOGLOBIN, REDUCTIONS IN SICKLE
HEMOGLOBIN
Further company coverage: BEAM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beam Therapeutics
See all newsBeam Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Beam Therapeutics Q1 net loss narrows beating analyst estimates
U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings
U.S. STOCKS ON THE MOVE-BWX, Generac, Cintas
U.S. STOCKS ON THE MOVE-Arm, On Holding, Sarepta